MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Abstract
In microorganisms, evolutionarily conserved mechanisms facilitate adaptation to harsh conditions through stress-induced mutagenesis (SIM). Analogous processes may underpin progression and therapeutic failure in human cancer. We describe SIM in multiple in vitro and in vivo models of human cancers under nongenotoxic drug selection, paradoxically enhancing adaptation at a competing intrinsic fitness cost. A genome-wide approach identified the mechanistic target of rapamycin (MTOR) as a stress-sensing rheostat mediating SIM across multiple cancer types and conditions. These observations are consistent with a two-phase model for drug resistance, in which an initially rapid expansion of genetic diversity is counterbalanced by an intrinsic fitness penalty, subsequently normalizing to complete adaptation under the new conditions. This model suggests synthetic lethal strategies to minimize resistance to anticancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mTOR is frequently activated in cancer, stimulates cell growth, facilitates adaptive evolution, and contributes to tumor metabolic reprogramming by rewiring glucose, amino acid, nucleotide, fatty acid, and lipid metabolism.224,225”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [225]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Research works printed but not linked: 1
- 10.1038/nm.3841 · DOI · Paper page
Cited by
Non-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
“This in turn leads to increased genomic instability and a temporary increase of the mutation rate in DTPs, thus momentarily increasing the likelihood of resistance mechanisms being acquired 10,17,188 (Fig.”
InfluentialHe, J., Qiu, Z., Fan, J., Xie, X., Sheng, Q., & Sui, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01891-4 · Cited by 160
“47,48 Furthermore, multiple studies 13,49 – 51 have con fi rmed the generation of the DTP cells under drug induction, with numerous factors inducing cancer cells to transition into the DTP cells, making them a recognized potential source of drug resistance.”
BackgroundGerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 110
“Emerging evidence suggests that rapid adaptation to targeted drugs by non-genetic mechanisms promotes sustained survival of persister cells, contributes to residual disease, and facilitates emergence of resistance mutations responsible for disease recurrence in patients (Pazarentzos and Bivona, 2015; Russo et al., 201…”
BackgroundNoronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0111 · Cited by 117
“Furthermore, the mechanistic target of rapamycin was identified as a stress-sensing rheostat that mediates SIM across multiple cancer types (6).”
BackgroundPARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
Risdon, E. N., Chau, C. H., Price, D. K., Sartor, O. A., & Figg, W. D. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0697 · Cited by 117
“A recent study investigating mechanisms of cancer treatment resistance supports a potentially synthetically lethal relationship between PARP inhibition and the mTOR signaling pathway, which orchestrates stress-induced mutagenesis in response to stress that increases cell-to-cell variability, enabling adaptation in res…”
BackgroundMapping genomic and epigenomic evolution in cancer ecosystems
Ushijima, T., Clark, S. J., & Tan, P. B. O. (2021) · Science · doi:10.1126/science.abh1645 · Cited by 97
Stress-Induced Mutagenesis, Gambler Cells, and Stealth Targeting Antibiotic-Induced Evolution
Pribis, J. P., Zhai, Y., Hastings, P. J., & Rosenberg, S. M. (2022) · mBio · doi:10.1128/mbio.01074-22 · Cited by 78
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Puliafito, A., Lamba, S., Erriquez, J., Bertotti, A., Gherardi, M., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01105-z · Cited by 78
“This in line with previous findings showing that the tumor mutational burden is not strongly increased in cells that acquired therapy resistance 12,13 .”
InfluentialWang, N., Wu, S., Huang, L., Hu, Y., He, X., He, J., Hu, B., Xu, Y., Rong, Y., Yuan, C., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01117-x · Cited by 62
“The microbiome may undergo a similar evolution in the stressful tumor microenvironment [180, 181], and this co-evolution presents a more complex and refined challenge to deciphering the role of the intratumoral micro-biome in tumors.”
The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 63
Islam, S., Wang, S., Bowden, N. A., Martin, J. H., & Head, R. J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14964 · Cited by 50
“Moreover, drug resistance driven by enhanced adaption is undetectable by most preclinical assays of anti-cancer activity.(39) We have described the relationship between hypermutation and DNA repair with cellular-based drug resistance previously.”
BackgroundThe Hallmarks of Cancer as Ecologically Driven Phenotypes
Somarelli, J. A. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.661583 · Cited by 52
“For example, by using sequential treatment paradigms to first force cells into persistence/dormancy-like phenotypes, and then target these persistent cells with a secondary agent (Cipponi et al., 2020; Shen et al., 2020), it may be possible to prolong survival for patients with therapy-resistant or micrometastatic dis…”
Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment
Russo, M., Sogari, A., & Bardelli, A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1588 · Cited by 51
“…by unicellular organisms represent phylogenetically conserved mechanisms of survival, then conceptual interpretation of cancer as a community of unicellular organisms can be inspirational for developing new anticancer therapies to curb or restrict the emergence of drug resistance (81, 82).”
InfluentialWang, Y., Luo, M., Wang, F., Tong, Y., Li, L., Shu, Y., Qiao, K., Zhang, L., Yan, G., Liu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34747-y · Cited by 42
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol, K., Pawlik, P., & McGranahan, N. (2022) · Genome Medicine · doi:10.1186/s13073-022-01138-3 · Cited by 48
“by Cisplatin [51]); Stress-induced accelerated evolution [53, 54] Immunosuppression (platinum adducts cause apoptosis of lymphocytes [47–49]); Stress-induced accelerated evolution [53, 54]”
BackgroundEvolving insights: how DNA repair pathways impact cancer evolution
Zhou, J., Zhou, X. A., Zhang, N., & Wang, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0177 · Cited by 45
The Mutagenic Impact of Environmental Exposures in Human Cells and Cancer: Imprints Through Time
Huber, A. R., van Hoeck, A., & van Boxtel, R. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.760039 · Cited by 43
“, 2015; Hawkins and Miles, 2021) or altered expression of DNA replication and repair enzymes, elevating mutational loads (Russo et al., 2019; Cipponi et al., 2020).”
BackgroundLv, G., Wang, Q., Lin, L., Ye, Q., Li, X., Zhou, Q., Kong, X., Deng, H., You, F., Chen, H., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01473-0 · Cited by 43
“Recent evidence links mTOR to drug resistance 23–25 .”
BackgroundDrug-induced resistance evolution necessitates less aggressive treatment
Kuosmanen, T., Cairns, J., Noble, R., Beerenwinkel, N., Mononen, T., & Mustonen, V. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009418 · Cited by 38
“Recently, similar findings were reported also in cancer in the context of targeted cytostatic therapies [16, 17].”
Identifying predictors of glioma evolution from longitudinal sequencing
Mu, Q., Chai, R., Pang, B., Yang, Y., Liu, H., Zhao, Z., Bao, Z., Song, D., Zhu, Z., Yan, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4181 · Cited by 39
“Hypermutation (HM), characterized by a high mutational burden with special mutational signatures and somatic mismatch repair (MMR) deficiency, was detected in a subset of temozolomide (TMZ)–treated recurrent gliomas, highlighting the role of stress-induced mutagenesis in shaping adaptive glioma evolution (12, 13).”
BackgroundSublethal engagement of apoptotic pathways in residual cancer
Killarney, S. T., Tait, S. W. G., Green, D. R., & Wood, K. C. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.07.005 · Cited by 42
Bertrums, E. J. M., Huber, A. R., de Kanter, J. K., Brandsma, A. M., van Leeuwen, A. J. C. N., Verheul, M., van den Heuvel‐Eibrink, M. M., Oka, R., van Roosmalen, M. J., de Groot‐Kruseman, H. A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0120 · Cited by 43
“Thus, the origin for this indirect mutagenesis may be replicative stress (45) or stress-induced mutagenesis (46).”
BackgroundSmart drug delivery systems to overcome drug resistance in cancer immunotherapy
Yi, W., Yan, D., Wang, D., & Li, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0009 · Cited by 32
Exosomal miR‐222‐3p contributes to castration‐resistant prostate cancer by activating mTOR signaling
Wang, W., Kong, P., Feng, K., Liu, C., Gong, X., Sun, T., Duan, X., Sang, Y., Jiang, Y., Li, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15948 · Cited by 28
Drugging evolution of antibiotic resistance at a regulatory network hub
Zhai, Y., Pribis, J. P., Dooling, S. W., García-Villada, L., Minnick, P. J., Xia, J., Liu, J., Mei, Q., Fitzgerald, D. M., Herman, C., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg0188 · Cited by 27
Stimulation of adaptive gene amplification by origin firing under replication fork constraint
Whale, A. J., King, M. R., Hull, R. M., Krueger, F., & Houseley, J. M. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1257 · Cited by 27
“However, neither does this constitute a stress-induced mutational pathway equivalent to the bacterial SOS response or recent reports of adaptive mutability during chemotherapy (103-105).”
BackgroundMemory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma
Hastings, J. F., Latham, S. L., Kamili, A., Wheatley, M. S., Han, J. Z. R., Wong, M., Phimmachanh, M., Nobis, M., Pantarelli, C., Cadell, A. L., et al. (2023) · Science Advances · doi:10.1126/sciadv.abp8314 · Cited by 31
“All these mechanisms are likely to occur concurrently and may even display a degree of interdependency, where the initial survival of cells via nongenetic mechanisms may facilitate the accrual of somatic mutations through a form of adaptive mutagenesis ( 37 ).”
Self-citationApplications of single-cell technologies in drug discovery for tumor treatment
Liu, B., Hu, S., & Wang, X. (2024) · iScience · doi:10.1016/j.isci.2024.110486 · Cited by 25
Liang, X., Qin, Q., Liu, B., Li, X., Zeng, L., Wang, J., Kong, L., Zhong, D., & Sun, L. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00577-1 · Cited by 25
Reverting to single-cell biology: The predictions of the atavism theory of cancer
Bussey, K. J., & Davies, P. C. W. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.08.002 · Cited by 32
“demonstrated that treatment with non-DNA damaging agents nevertheless increased the number of doublestrand breaks observed in prostate, breast, melanoma, and gastrointestinal stromal tumors (Cipponi et al., 2020), implying that the mutational burden is self-inflicted, consistent with our hypothesis that cancer is (at…”
BackgroundZhu, Z. Y., Song, H., & Xu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641077 · Cited by 28
“Mutagenesis in malignancies provides a pool for the immune system and selection of anticancer therapies (4).”
BackgroundComprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
Gomes, I. N. F., Oliveira, R. J. D. S., da Silva, L. S., Martinho, O., Evangelista, A. F., Lengert, A. V. H., Leal, L. F., Silva, V. A. O., dos Santos, S. P., Nascimento, F. C., et al. (2022) · Cells · doi:10.3390/cells11010154 · Cited by 27
“A recent study associated MTOR overexpression in the TKI inhibitors resistance process, demonstrating that stress-induced mutagenesis contributes to adaptive evolution in cancer for drug resistance [65].”
BackgroundMutational signatures and processes in hepatobiliary cancers
Zhuravleva, E., O’Rourke, C. J., & Andersen, J. B. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00587-w · Cited by 26
COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
Hancock, J. L., Kalimutho, M., Straube, J., Lim, M., Gresshoff, I., Saunus, J. M., Lee, J. S., Lakhani, S. R., Simpson, K. J., Bush, A. I., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02663-8 · Cited by 22
“To identify changes in shRNA abundance, genomic DNA isolated from day zero (starting material) and day 14 acini was used to amplify shRNA sequences as per standard methods [31, 35].”
MethodXu, Z., Shi, Y., Zhu, L., Luo, J.-H., Hu, Q., Jiang, S., Xiao, M., Jiang, X., Wang, H., Xu, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217075 · Cited by 24
The many faces of cancer evolution
Ciriello, G., & Magnani, L. (2021) · iScience · doi:10.1016/j.isci.2021.102403 · Cited by 22
Gou, R., Li, X., Dong, H., Hu, Y., Liu, O., Liu, J., & Lin, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.936550 · Cited by 19
Bechelli, J., Rumfield, C. S., Walker, D. H., Widen, S. G., Khanipov, K., & Fang, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638469 · Cited by 18
“The mTOR signaling pathway is widely expressed in tissues and cells of mammalian hosts, and functions as an evolutionarily conserved sensor of environmental and endogenous stress (47).”
BackgroundMarrocco, I., Giri, S., Nieves, A. S., Gupta, N., Rudnitsky, A., Haga, Y., Romaniello, D., Sekar, A., Zerbib, M., Oren, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101142 · Cited by 22
“(3) According to a recent study, stress-inducedmutagenesis (SIM) was identified in multiple models of human cancer.(59) Furthermore, the cited study identified the mechanistic target of rapamycin as the molecule that mediates SIM.”
BackgroundLi, X., Nie, T., Lu, F., Huang, L. H., Shi, X., Ren, D., Lu, J., Li, X., Xu, T., Cui, B., et al. (2023) · Autophagy · doi:10.1080/15548627.2023.2259735 · Cited by 19
“In many cancers, persistent RRAG GTPases activation contributes to uncontrolled MTORC1 signaling for cancer cell growth and proliferation by evasion of metabolic checks [6,7,25,26].”
BackgroundGene Panel of Persister Cells as a Prognostic Indicator for Tumor Repopulation After Radiation
Zhao, Y., Song, Y., Zhao, R., Zhao, M., & Huang, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.607727 · Cited by 22
“An elegant work recently using whole-genome RNAi screening identified MTOR as a common orchestrator in stress-induced genomic instability, accelerating the adaptation of cancers in cytotoxic condition and facilitating the cancer resistance to different oncotherapy (44).”
BackgroundChong, Z. X., Ho, W. Y., Yeap, S.-K., Wang, M., Chien, Y., Verusingam, N. D., & Ong, H. K. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000535 · Cited by 18
“131”
The Immune System and Responses to Cancer: Coordinated Evolution
Coventry, B. J., Ashdown, M., Henneberg, M., & Davies, P. C. W. (2015) · F1000Research · doi:10.12688/f1000research.6718.3 · Cited by 22
Metabolic Adaptation and Cellular Stress Response As Targets for Cancer Therapy
Lee, C. J., & Yoon, H. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230153 · Cited by 17
“The role of mTORC1 is crucial in promoting cancer growth and regulating diverse metabolic pathways, including glutamine metabolism [53,63].”
BackgroundTrigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Genome biology · doi:10.1186/s13059-024-03247-1 · Cited by 15
Self-citationLi, J., Zhang, L., Shang, Y., Liu, J., & Zhao, H. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70586 · Cited by 17
“…of genetic and signalling pathway perturbations, encompassing heightened drug efflux mediated by transporters such as ABCB1 (P-gp), 3,4 impaired drug uptake via solute carrier transporters, 5 augmented DNA damage repair machinery 6 and dysregulated apoptotic signalling, 7 among other mechanisms.”
Cheng, A., Rao, Q., Liu, Y., Huang, C., Li, J., Huo, C., Lin, Z., & Lu, H. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.011 · Cited by 13
Guo, X., Bian, X., Li, Y., Zhu, X. M., & Zhou, X. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167098 · Cited by 16
YAP Promotes Chemoresistance to 5-FU in Colorectal Cancer Through mTOR/GLUT3 Axis
Xu, Q., Jin, Z., Yuan, Z., Yu, Z., Gao, J., Zhao, R., Li, H., Ren, H., Cao, B., Wei, B., et al. (2024) · Journal of Cancer · doi:10.7150/jca.100179 · Cited by 12
“The KEGG analysis demonstrated that the YAP-related genes were enriched in the DNA replication and PI3K/AKT/mTOR pathways (Figure 3D). mTOR pathway activation has been shown to induce improper DNA replication in various cancer cells, which contributes to drug resistance [23].”
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Altintas, D. M., & Comoglio, P. M. (2023) · Cancers · doi:10.3390/cancers15184672 · Cited by 11
Cancer as a form of life: Musings of the cancer and evolution symposium
Paul, D. (2021) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2021.05.003 · Cited by 15
Quantifying and visualising the nuances of cellular dynamics in vivo using intravital imaging
Murphy, K. J., Reed, D. A., Trpceski, M., Herrmann, D., & Timpson, P. (2021) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.04.007 · Cited by 12
Self-citationAdaptive evolution of Candida albicans through modulating TOR signaling
Zhang, Y., Yang, L., Zhao, Y., Xiong, K., Cui, H., Wang, T., Liu, X., Su, C., & Lü, Y. (2025) · mBio · doi:10.1128/mbio.03947-24 · Cited by 10
HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
Waitman, K. B., de Almeida, L. C., Primi, M. C., Carlos, J. A. E. G., Ruiz, C. H., Kronenberger, T., Laufer, S., Goettert, M. I., Poso, A., Vassiliades, S. V., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115935 · Cited by 10
Seita, A., Nakaoka, H., Okura, R., & Wakamoto, Y. (2021) · PLoS ONE · doi:10.1371/journal.pone.0236534 · Cited by 15
“It is an intriguing question whether the slow-cycling phenotype is a prerequisite for the acquisition of stronger drug resistance, possibly mediated by drastic changes in metabolic states or triggering adaptive mutations [41, 42].”
BackgroundNavigating Nongenetic Plasticity in Cancer Drug Resistance
Sun, H., Kumari, N., Melzer, M. E., Backman, V., & Goyal, Y. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071924-084617 · Cited by 12
Han, X., Du, J., Zheng, Y.-D., Dai, J., Lin, S.-W., Zhang, B., Zhong, F., Lin, Z.-G., Jiang, S., Wei, W., et al. (2021) · BioMed Research International · doi:10.1155/2021/5089371 · Cited by 9
“Drugmediated stress-induced mutagenesis probably acts as a double-edged sword, causing neoplasm necrosis in the context of belinostat intervention [58].”
BackgroundMany Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas
Vachtenheim, J., & Ondrušová, Ľ. (2021) · Life · doi:10.3390/life11050424 · Cited by 10
“The PI3K/AKT pathway has been recently identified as a key factor in stress-induced mutagenesis and stress-sensing mediating resistance in many types of cancer [59].”
BackgroundNangia, V., Ashraf, H. M., Marikar, N. C., Passanisi, V. J., Christopher, R., & Spencer, S. L. (2025) · Science Signaling · doi:10.1126/scisignal.adw3231 · Cited by 11
DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth
Williams, A. F., Gervasio, D. A. G., Turkal, C. E., Stuhlfire, A. E., Wang, M. X., Mauch, B. E., Plawat, R., Nguyen, A. H., Paw, M. H., Hairani, M., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01810-x · Cited by 12
“6m–o and Supplementary Tables 6–9).”
InfluentialSystems Biology: Functional Strategies of Living Organisms
Konieczny, L., Roterman-Konieczna, I., & Spólnik, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-31557-2 · Cited by 12
Clonal selection parallels between normal and cancer tissues
Salavaty, A., Azadian, E., Naik, S. H., & Currie, P. D. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.01.007 · Cited by 12
Fujisawa, F., Kunimasa, K., Kano, R., Sato, Y., Kusama, H., Nishio, M., Matsui, S., Yoshinami, T., Kittaka, N., Nakamura, H., et al. (2021) · Breast Cancer · doi:10.1007/s12282-020-01200-1 · Cited by 7
Blackstone, N. W., & Gutterman, J. U. (2020) · BioEssays · doi:10.1002/bies.202000160 · Cited by 6
“In many ways, their behavior suggests atavistic unicellular organisms,[5,8,51] exhibiting striking parallels to yeasts—polyphyletic, unicellular, fast-replicating, and predominately glycolytic.”
BackgroundEscape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance
Channathodiyil, P., May, K., Segonds-Pichon, A., Smith, P. D., Cook, S. J., & Houseley, J. M. (2022) · NAR Cancer · doi:10.1093/narcan/zcac032 · Cited by 6
“Reduced expression of high-fidelity DNA replication and repair genes has been observed in drug-arrested cell populations (28,30), which suggests that the sporadic entry of drug-treated cells into S phase may occur when replication factors are limited.”
BackgroundOptimal dosing of anti-cancer treatment under drug-induced plasticity
Gunnarsson, E. B., Magnússon, B. V., & Foo, J. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00571-5 · Cited by 11
“Drug induction is already well known in the context of genetic mutations, where both anti-cancer and anti-bacterial drugs have been observed to cause genomic instability or mutagenesis , referring to an elevated mutation rate occurring as a result of the stress imposed by the treatment 18 – 21 .”
Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer
Cisneros, L. H., Vaske, C. J., & Bussey, K. J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.932763 · Cited by 4
Walen, K. H. (2022) · Journal of Cancer Therapy · doi:10.4236/jct.2022.131004 · Cited by 5
Walen, K. H. (2020) · Journal of Cancer Therapy · doi:10.4236/jct.2020.117036 · Cited by 3
Spatial immune heterogeneity in a mouse tumor model after immunotherapy
Šmahel, M., Johari, S. D., Šmahelová, J., Pfeiferová, L., & Nunvář, J. (2024) · Cancer Science · doi:10.1111/cas.16421 · Cited by 2
“This phenomenon was mediated by the inhibition of the mechanistic target of rapa - mycin signaling, 9 which impairs DNA damage response.”
The Potential Links between lncRNAs and Drug Tolerance in Lung Adenocarcinoma
Davis, W. J. H., Drummond, C. J., Diermeier, S. D., & Reid, G. (2024) · Genes · doi:10.3390/genes15070906 · Cited by 4
“Downstream of the AXL receptor is the mammalian target of rapamycin (mTOR) [138] with recent evidence suggesting both are central players in the adaptive mutability of DTPs [78].”
BackgroundInfluentialli, M., Yang, N., Li, H., zhou, W., Li, L., liu, L., fang, F., Xu, L., Yao, G., Chen, Z., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-850531/v1 · Cited by 2
Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
Crisafulli, G., & Siravegna, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1260158 · Cited by 2
“This adaptive response allows the tumour to evade the effect of the targeted therapy and continue proliferating, ultimately leading to treatment failure (18, 19, 21).”
BackgroundLiu, Y., Goretsky, A., Keşküş, A. G., Malikić, S., Ahmad, T., Gertz, E. M., Mehrabadi, F. R., Kelly, M. C., Hernandez, M., Seibert, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672865 · Cited by 2
“Alternatively, whole genome sequencing of single-cell derived subclones have been used to precisely trace subclonal differentiation with high sequencing depth [102, 74, 13].”
Fabbri, L., Lagadec, L., Guérin, E., Lecourt, H., Baïlle, D., Besse, L., Messaoudi, C., Désaubry, L., Hamdan, H. A., Roy, S., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00479-5 · Cited by 2
“…subjected to targeted therapies, this repression has been shown to occur at the transcriptional level, at least for speci fi c HDR factors such as RAD51 and BRCA1/2, and to be independent of cell cycle distribution (Cipponi et al, 2020; Maertens et al, 2019; Makino et al, 2020; Russo et al, 2019).”
InfluentialJavadi, P., & Azadi, A. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103452 · Cited by 1
“Other mechanisms of resistance include mutation in gene expression, epigenetic changes, and drug efflux, which result in reduced intracellular drug accumulation [21].”
Interrelationship in Organized Biological Systems
Konieczny, L., Roterman‐Konieczna, I., & Spólnik, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-31557-2_5 · Cited by 2
Metabolism and Multicellularity Revisited
Blackstone, N. W. (2022) · Springer eBooks · doi:10.1007/978-3-031-06059-5_10 · Cited by 1
MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent gliomaPreprint
Wang, J., Mu, Q., Chai, R., Liu, H., Yang, Y., Zhao, Z., Lui, M. H., Bao, Z., Song, D., Jiang, B., et al. (2021) · doi:10.21203/rs.3.rs-138020/v1 · Cited by 2
µ Seq: Universal mutation rate quantification via deep sequencing of a single clonal expansionPreprint
Pompei, S., Geroldi, A., Rivetti, P., Grassi, E., Vurchio, V., Tallarico, G., Corti, G., Tattini, L., Liti, G., Bertotti, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.17.649315 · Cited by 1
Drug-induced colorectal cancer persister cells show increased mutation ratePreprint
Russo, M., Pompei, S., Sogari, A., Corigliano, M., Crisafulli, G., Bertotti, A., Gherardi, M., Nicolantonio, F. D., Bardelli, A., & Lagomarsino, M. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.17.444478 · Cited by 2
Heidegger y Ortega y Gasset: notas incompletas sobre historia como hermeneútica
Miranda, L. U. (2006) · Dialnet (Universidad de la Rioja) · Cited by 2
Traditional therapies and their moderation
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00015-x
The Immune System and Responses to Cancer: Coordinated Evolution
Coventry, B. J., Ashdown, M. L., & Henneberg, M. (2020) · F1000Research · doi:10.12688/f1000research.6718.2 · Cited by 1
Yan, M., & Liu, Q. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0975-5 · Cited by 1
“On the other hand, both linear and branched tumor evolution result in heterogeneous tumors, which has been found in various tumor types, including breast, prostate, pancreatic and clear cell renal cell carcinoma [30].”
BackgroundNoronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2023) · doi:10.1158/2159-8290.c.6549711.v1
Noronha, A., Nataraj, N. B., Lee, J. S., Zhitomirsky, B., Oren, Y., Oster, S. K., Lindzen, M., Mukherjee, S., Will, R. D., Ghosh, S., et al. (2023) · doi:10.1158/2159-8290.c.6549711
Life, the genome and everything
Rosenberg, S. M. (2023) · Journal of Bacteriology · doi:10.1128/jb.00272-23
Evolvability in the context of antibiotic resistance
van Eldijk, T. J. B. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.925124601
Drivers of Spatial Immune Heterogeneity in a Mouse Tumor Model after ImmunotherapyPreprint
Šmahel, M., Johari, S. D., Šmahelová, J., Pfeiferová, L., & Nunvář, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4855460
Wu, Y., Gao, J., Su, Z., Gao, A., Zhao, J., Qiao, G., Ye, M., Liu, D., & Xu, J. (2025) · IUBMB Life · doi:10.1002/iub.70033
DFFB suppresses interferon to enable cancer persister cell regrowthPreprint
Williams, A. F., Gervasio, D. A. G., Turkal, C. E., Stuhlfire, A. E., Wang, M., Mauch, B. E., Plawat, R., Nguyen, A. H., Paw, M. H., Hairani, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.670603
Modelling phenotypic heterogeneity and cell-state transitions during cancer progression
Gopalan, V., Goyal, S., & Rehman, S. K. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192867636.003.0010
Trigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713888
Self-citationHancock, J. L., Kalimutho, M., Straube, J., Lim, M., Gresshoff, I., Saunus, J. M., Lee, J. S., Lakhani, S. R., Simpson, K. J., Bush, A. I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22655304
Trigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713885
Self-citationTrigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713882
Self-citationThe Emerging Role of mTOR in Shaping the Cancer Cell Secretome and Plasticity
Cooper, T. T., Topisirović, I., & Postovit, L.-M. M. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2699146
Metadata
- Authors
- Cipponi, A., Goode, D. L., Bedo, J., McCabe, M. J., Pajic, M., Croucher, D. R., Rajal, A. G., Junankar, S. R., Saunders, D. N., Lobachevsky, P., Papenfuss, A. T., Nessem, D., Nobis, M., Warren, S. C., Timpson, P., Cowley, M., Vargas, A. C., Qiu, M. R., Generali, D. G., Keerthikumar, S., Nguyen, U., Corcoran, N. M., Long, G. V., Blay, J.-Y., & Thomas, D. M.
- Affiliations
- Garvan Institute of Medical Research (AU)
- The University of Melbourne (AU)
- Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
- UNSW Sydney (AU)
- Peter MacCallum Cancer Centre (AU)
- Douglass Hanly Moir Pathology (AU)
- University of Trieste (IT)
- The Royal Melbourne Hospital (AU)
- The University of Sydney (AU)
- Centre Léon Bérard (FR)
- Corresponding author
- Cipponi, Arcadi
- Thomas, David M.
- ORCID
- Cipponi, Arcadi
- Goode, David L.
- Bedo, Justin
- McCabe, Mark J.
- Pajic, Marina
- Croucher, David R.
- Rajal, Alvaro Gonzalez
- Junankar, Simon R.
- Saunders, Darren N.
- Lobachevsky, Pavel
- Papenfuss, Anthony T.
- Nessem, Danielle
- Nobis, Max
- Warren, Sean C.
- Timpson, Paul
- Cowley, Mark
- Vargas, Ana C.
- Qiu, Min R.
- Generali, Daniele G.
- Keerthikumar, Shivakumar
- Nguyen, Uyen
- Corcoran, Niall M.
- Long, Georgina V.
- Blay, Jean-Yves
- Thomas, David M.
- Venue
- Science
- Published
- 2020-06-05
- Volume
- 368
- Issue
- 6495
- Pages
- 1127-1131
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3033942938
- Cited by
- 103
- References
- 74
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 16 · 2021: 23 · 2020: 8
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Funders
- Cancer Australia (1143699)
- Australian national health and medical research council (APP1088353, APP1162860)
- Girgenshon Foundation
- MEDnoTE Spin-Off University of Trieste (N/A)
- Australian national health and medical resesrach council (APP1162556)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- stress-induced mutagenesis, mTOR signaling, drug resistance, synthetic lethality, genome-wide screen, tumor evolution
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, DNA Repair, Humans, Neoplasms, Selection, Genetic, Signal Transduction, Mutagenesis, Drug Resistance, Neoplasm, Cell Line, Tumor, Genome-Wide Association Study, Genetic Fitness, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.